News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
227,946 Results
Type
Article (7168)
Company Profile (16)
Press Release (220762)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63142)
Career Advice (294)
Deals (14771)
Drug Delivery (28)
Drug Development (36798)
Employer Resources (24)
FDA (6412)
Job Trends (4909)
News (121830)
Policy (11629)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
Academia (567)
Accelerated approval (2)
Adcomms (7)
Allergies (35)
Alliances (14771)
ALS (28)
Alzheimer's disease (600)
Antibody-drug conjugate (ADC) (40)
Approvals (6458)
Artificial intelligence (102)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4609)
BIOSECURE Act (2)
Biosimilars (21)
Biotechnology (18)
Bladder cancer (49)
Brain cancer (14)
Breast cancer (106)
Cancer (1133)
Cardiovascular disease (70)
Career advice (258)
Career pathing (4)
CAR-T (89)
Cell therapy (215)
Cervical cancer (12)
Clinical research (31188)
Collaboration (303)
Compensation (89)
Complete response letters (7)
COVID-19 (722)
CRISPR (18)
C-suite (75)
Cystic fibrosis (37)
Data (1278)
Denatured (1)
Depression (19)
Diabetes (109)
Diagnostics (2228)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (48)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (40)
Earnings (33310)
Editorial (13)
Employer branding (1)
Employer resources (19)
Events (31012)
Executive appointments (247)
FDA (7077)
Featured Employer (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (268)
Gene editing (46)
Generative AI (10)
Gene therapy (127)
GLP-1 (184)
Government (1253)
Grass and pollen (2)
Guidances (35)
Healthcare (6145)
Huntington's disease (5)
IgA nephropathy (14)
Immunology and inflammation (36)
Indications (17)
Infectious disease (784)
Inflammatory bowel disease (59)
Inflation Reduction Act (5)
Influenza (24)
Intellectual property (51)
Interviews (45)
IPO (8033)
IRA (17)
Job creations (570)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (40)
Leadership (3)
Legal (2100)
Liver cancer (39)
Lung cancer (161)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (104)
MASH (37)
Medical device (4582)
Medtech (4583)
Mergers & acquisitions (7091)
Metabolic disorders (280)
Multiple sclerosis (38)
NASH (8)
Neurodegenerative disease (26)
Neuropsychiatric disorders (4)
Neuroscience (804)
NextGen: Class of 2025 (1500)
Non-profit (712)
Northern California (1265)
Obesity (139)
Opinion (75)
Ovarian cancer (53)
Pain (35)
Pancreatic cancer (46)
Parkinson's disease (67)
Partnered (5)
Patents (133)
Patient recruitment (61)
Peanut (17)
People (14530)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9955)
Phase II (13722)
Phase III (10288)
Pipeline (730)
Policy (33)
Postmarket research (796)
Preclinical (3629)
Press Release (9)
Prostate cancer (50)
Psychedelics (11)
Radiopharmaceuticals (118)
Rare diseases (156)
Real estate (1003)
Recruiting (7)
Regulatory (9146)
Reports (13)
Research institute (510)
Resumes & cover letters (39)
Rett syndrome (3)
RNA editing (2)
RSV (16)
Schizophrenia (26)
Series A (44)
Series B (30)
Service/supplier (2)
Sickle cell disease (23)
Southern California (1102)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (676)
Stomach cancer (5)
Supply chain (25)
Tariffs (3)
The Weekly (1)
United States (10557)
Vaccines (167)
Venture capitalists (5)
Weight loss (77)
Women's health (6)
Worklife (4)
Date
Today (24)
Last 7 days (286)
Last 30 days (1126)
Last 365 days (15767)
2025 (4613)
2024 (16932)
2023 (19102)
2022 (22239)
2021 (23635)
2020 (21800)
2019 (14449)
2018 (10636)
2017 (11459)
2016 (9542)
2015 (11736)
2014 (8102)
2013 (5877)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (54)
Arkansas (3)
Asia (17550)
Australia (4848)
California (2858)
Canada (1116)
China (237)
Colorado (121)
Connecticut (161)
Delaware (58)
Europe (27991)
Florida (422)
Georgia (68)
Idaho (6)
Illinois (207)
India (20)
Indiana (123)
Japan (89)
Kansas (14)
Kentucky (5)
Louisiana (5)
Maine (36)
Maryland (350)
Massachusetts (2041)
Michigan (51)
Minnesota (102)
Missouri (36)
Montana (11)
Nebraska (8)
Nevada (39)
New Hampshire (36)
New Jersey (985)
New Mexico (3)
New York (907)
North Carolina (392)
North Dakota (2)
Northern California (1265)
Ohio (62)
Oklahoma (1)
Oregon (7)
Pennsylvania (674)
Puerto Rico (6)
Rhode Island (8)
South America (302)
South Carolina (11)
Southern California (1102)
Tennessee (42)
Texas (428)
Utah (68)
Virginia (76)
Washington D.C. (17)
Washington State (343)
West Virginia (2)
Wisconsin (11)
227,946 Results for "nodthera limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
NodThera announces positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters.
June 12, 2024
·
4 min read
Business
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, announces the appointment of Daniel Swisher as Chief Executive Officer, to strengthen the Company’s commercial capabilities, effective immediately.
May 28, 2024
·
5 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
NodThera today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).
March 7, 2024
·
5 min read
Press Releases
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
August 5, 2024
·
2 min read
Press Releases
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
August 1, 2024
·
4 min read
Parkinson’s disease
Breaking the Cycle of Inflammation in Parkinson’s Disease
Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.
July 15, 2024
·
4 min read
·
Jill Drachenberg
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
April 14, 2025
·
5 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Drug Development
NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249
NodThera, a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation, today announced positive Phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249.
September 21, 2022
·
3 min read
1 of 22,795
Next
